LifeWave X39 patch claims vs. what the science actually shows

What's this video probably claiming?

Based on the caption and hashtags, @liz.sanford is almost certainly promoting the LifeWave X39 patch, a product marketed around the idea that it emits specific wavelengths of light that "activate" your body's own GHK-Cu copper peptide production. The bullet points hit every wellness buzzword in one go: stem cell activation, lung protection, anti-cancer-adjacent language ("anti-fast growing cells"), neuroprotection, antioxidant effects, and skin and hair improvement. The word "LIGHT" DM-funnel is a classic multi-level marketing (MLM) recruitment mechanic. LifeWave is, in fact, a network marketing company, and X39 is its flagship product, priced around $150 per month. The "patented" framing is doing a lot of heavy lifting here, as having a patent on a device says nothing about whether it works as claimed.

What does the science actually show?

GHK-Cu (glycine-histidine-lysine copper peptide) is a legitimately interesting molecule. Pickart and Margolina (2018, Biomedicines) reviewed decades of research showing GHK-Cu influences wound healing, collagen synthesis, and anti-inflammatory gene expression in cell cultures and some animal models. Dou et al. (2021, Frontiers in Aging Neuroscience) found neuroprotective signals in preclinical models. The problem is the delivery mechanism claimed here. The X39 patch is not a transdermal peptide delivery system. LifeWave's own patents describe a phototherapy concept: the patch allegedly reflects infrared wavelengths from body heat back into the skin to stimulate endogenous peptide production. There is no peer-reviewed, independently replicated clinical trial demonstrating that a light-reflecting adhesive patch meaningfully elevates circulating GHK-Cu levels in living humans. That gap between the molecule's real biology and the product's claimed mechanism is enormous.

Where does the social media noise diverge from clinical reality?

The phrase "activate stem cells" is doing serious regulatory work in this caption. LifeWave's own marketing has made this claim, and it has drawn scrutiny from the FTC and various international regulators. A LifeWave-funded pilot study (Haltiwanger, 2021) claimed measurable changes in stem cell markers, but it was unpublished in a peer-reviewed journal at the time of wide circulation, had no control group, and was authored by a company-affiliated researcher. The "anti-fast growing cells" bullet appears to reference GHK-Cu's documented ability to downregulate certain oncogenic pathways in vitro (Pickart et al., 2012, Journal of Amino Acids), but extrapolating in-vitro cancer biology to a light-patch adhesive is not science, it is marketing. The lung protection claim likely references GHK-Cu's anti-fibrotic properties in animal models, none of which have been replicated in human clinical trials via any delivery route, let alone a patch.

What should you actually know?

If GHK-Cu genuinely interests you from a peptide therapy perspective, the honest conversation starts with actual delivery routes. Injectable and topical GHK-Cu formulations are the subject of real clinical investigation for wound healing and skin aging, though no large randomized controlled trials have established dosing protocols or confirmed systemic effects. The X39 patch, specifically, has not been evaluated in an independent, blinded, placebo-controlled human trial that has passed peer review. Spending $150 a month on an adhesive patch based on a funding-biased pilot study is a decision worth interrogating. The peptide science referenced in this video's claims is real and interesting. The product being sold based on that science is not the same thing as the science. Those are two different conversations, and conflating them, as this video appears to do, is where misinformation takes root.